Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 7.88 Billion | USD 44.58 Billion | 21.2% | 2024 |
The global oral proteins and peptides market size was worth around USD 7.88 Billion in 2024 and is predicted to grow to around USD 44.58 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 21.2% between 2025 and 2034.
The report analyzes the global oral proteins and peptides market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the oral proteins and peptides industry.
Peptides are short sequences of amino acids that govern a variety of actions in human bodies, plants, and microbes. Insulin, which regulates sugar metabolism, and cyclosporine, which prevents organ rejection after transplantation, are two examples of peptide medicines. Peptides are a multibillion-dollar business in the pharmaceutical industry.
Previously they used to administer as injections to avoid stomach enzyme breakdown. However, scientists have devised a way of producing peptides that are resistant to enzymatic breakdown and can be consumed orally.
Increase in chronic disease around the world can boost the demand for oral proteins and peptides
The growing prevalence of chronic disease is the prime factor that is fueling the demand for global oral proteins and peptides market. According to recent statistics, approximately 15% of individuals in the United States reported having at minimum two chronic medical illnesses in 2021, compared to only around 11% of older millennials. It is the primary cause of disability and death, as well as the $3.8 trillion in annual healthcare costs in the United States.
In addition to this, the increase in the geriatric population which is prone to chronic diseases including diabetes, digestive disorders, and many more are also contributing to the market growth. Moreover, factors such as expanding healthcare infrastructure, heavy investment in drug discovery & development, and an increase in spending on healthcare are fostering the growth of the market.
High costs associated with the development and formulation of peptide therapeutics may hinder the market growth.
In addition to physiological hurdles, the formulation is a significant problem in the manufacturing of commercial oral peptides. The physical and chemical stability of peptides is the most essential concern in formulation development, intending to allow the peptide to be stable during manufacturing processes.
In solution formulation, buffer solutions are commonly used to stabilize peptides. Furthermore, various excipients, such as arginine, histidine, and glycine, are required to be included in the formulation to increase solubility or prevent protein aggregation, which adds to the process cost.
Increasing research activities in oral peptide formulations may drive the market during the forecast period.
The global oral proteins and peptides market is rising due to increased government and private sector investment in research and development, as well as an increase in biopharmaceutical businesses throughout the world.
In addition to this, heavy investments in the launch of new therapeutic drugs for effective treatment, rise in the number of clinical trials, advancements in the technologies in drug development & research activities are also some of the additional factors that are expected to boost the market during the forecast period.
Difficulties with the metabolism and formulation of therapeutics pose a major challenge to market growth.
Peptides are a multibillion-dollar sector in the pharmaceutical industry, however, they can only be administered as injections to avoid stomach enzyme breakdown. Even though oral delivery of peptides has piqued the interest of pharmaceutical firms and research agencies, several factors hinder the progress of oral peptides, including gastrointestinal tract instability, poor penetrability through intestinal epithelia, and effort in formulation development.
Because of the inherent nature of the gastrointestinal tract, which is not only the prime site of nutrient uptake and food processing but also the first line of defense against infections and toxins. Such physiological barriers are the major impediments to oral absorption of peptides which poses a major challenge to the expansion of the market.
The global oral proteins and peptides market is bifurcated based on drug type, application, and region.
Based on the drug type, the global oral proteins and peptides market is divided into octreotide, insulin, calcitonin, plecanatide, and linaclotide. Among these products, insulin is expected to account for the largest share of the market. Linaclotide was the fastest growing segment in 2021 and is expected to grab a large share of total revenue in the coming years.
By application segment, the global oral proteins and peptides market is divided into hormonal disorders, diabetes, bone diseases, and gastric & digestive disorders. Diabetes was the leading application segment accounting for the largest revenue share in 2021. The outsized share of diabetes segment is primarily accredited to the high acceptance of oral insulin in diabetic population and relative increase in the prevalence of diabetes. The bone disease segment is expected to grow at the highest CAGR during the forecast period.
Report Attributes | Report Details |
---|---|
Report Name | Oral Proteins and Peptides Market |
Market Size in 2024 | USD 7.88 Billion |
Market Forecast in 2034 | USD 44.58 Billion |
Growth Rate | CAGR of 21.2% |
Number of Pages | 166 |
Key Companies Covered | Proxima Concepts Limited (Diabetology Ltd.), Allergan plc, Biocon Limited, Chiasma Inc., Generex Biotechnology Corp., Hovione Limited, Synergy Pharmaceuticals Inc., AstraZeneca plc, Novo Nordisk A/S, Tarsa Therapeutics Inc., Sanofi S.A., F. Hoffmann-La Roche AG, Synthetic Biologics Inc., Novartis International AG, and others. |
Segments Covered | By Drug Type, By Application, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America to lead the global market during the forecast period
North America is predicted to account for the largest share in the global oral proteins and peptides market during the forecast period. This is majorly due to an increase in the inclination of people for effective treatments and well-developed healthcare infrastructure. Further, the presence of a significant number of major players in the region, as well as growing consumer awareness of the main benefits of oral proteins and peptides, are expected to fuel the market's growth in the near future.
Furthermore, due to improved consumer knowledge of product advantages and an increasing geriatric population, the United States is likely to contribute considerably to the North American oral proteins and peptides market. Asia Pacific market is predicted to grow rapidly as a result of the rising population and strong private sector and government investment in R&D. Furthermore, the quickly increasing biopharmaceutical industry in the region is expected to fuel the growth of the oral proteins and peptides market throughout the forecast period.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the oral proteins and peptides market on a global and regional basis.
The global oral proteins and peptides market is dominated by players like:
The global oral proteins and peptides market is segmented as follows;
By Drug Type
By Application
By Region
FrequentlyAsked Questions
Leading players in the global oral proteins and peptides market include Proxima Concepts Limited (Diabetology Ltd.), Allergan plc, Biocon Limited, Chiasma Inc., Generex Biotechnology Corp., Hovione Limited, Synergy Pharmaceuticals Inc., AstraZeneca plc, Novo Nordisk A/S, Tarsa Therapeutics Inc., Sanofi S.A., F. Hoffmann-La Roche AG, Synthetic Biologics Inc., Novartis International AG, among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed